86 related articles for article (PubMed ID: 20039320)
1. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
[TBL] [Abstract][Full Text] [Related]
3. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
5. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
Chakrabarti L; Morgan C; Sandler AD
PLoS One; 2015; 10(6):e0129237. PubMed ID: 26079374
[TBL] [Abstract][Full Text] [Related]
6. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
7. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
Manukian G; Kivolowitz C; DeAngelis T; Shastri AA; Savage JE; Camphausen K; Rodeck U; Zarif JC; Simone NL
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1341-1349. PubMed ID: 33647370
[TBL] [Abstract][Full Text] [Related]
8. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.
Rakhmilevich AL; North RJ
Cancer Immunol Immunother; 1994 Feb; 38(2):107-12. PubMed ID: 7905789
[TBL] [Abstract][Full Text] [Related]
9. Near-term anti-CD25 monoclonal antibody administration protects murine liver from ischemia-reperfusion injury due to reduced numbers of CD4+ T cells.
Yang J; Wang X; Song S; Liu F; Fu Z; Wang Q
PLoS One; 2014; 9(9):e106892. PubMed ID: 25188007
[TBL] [Abstract][Full Text] [Related]
10. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory cytokines directly inhibit innate but not adaptive CD8+ T cell functions.
Freeman BE; Meyer C; Slifka MK
J Virol; 2014 Jul; 88(13):7474-84. PubMed ID: 24741101
[TBL] [Abstract][Full Text] [Related]
12. A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.
Grille S; Brugnini A; Nese M; Corley E; Falkenberg FW; Lens D; Chabalgoity JA
Cancer Immunol Immunother; 2010 Apr; 59(4):519-27. PubMed ID: 19768458
[TBL] [Abstract][Full Text] [Related]
13. 3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy.
Chamoto K; Wakita D; Ohkuri T; Uchinami Y; Matsushima K; Kitamura H; Nishimura T
Cancer Sci; 2010 Apr; 101(4):855-61. PubMed ID: 20151983
[TBL] [Abstract][Full Text] [Related]
14. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
Liu JY; Wu Y; Zhang XS; Yang JL; Li HL; Mao YQ; Wang Y; Cheng X; Li YQ; Xia JC; Masucci M; Zeng YX
Cancer Immunol Immunother; 2007 Oct; 56(10):1597-604. PubMed ID: 17440723
[TBL] [Abstract][Full Text] [Related]
15. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
[TBL] [Abstract][Full Text] [Related]
16. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.
Yan X; Zhang X; Wang Y; Li X; Wang S; Zhao B; Li Y; Ju Y; Chen L; Liu W; Meng S
Cancer Immunol Immunother; 2011 Dec; 60(12):1763-74. PubMed ID: 21789592
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model.
Yamanaka K; Hara I; Nagai H; Miyake H; Gohji K; Micallef MJ; Kurimoto M; Arakawa S; Kamidono S
Cancer Immunol Immunother; 1999 Sep; 48(6):297-302. PubMed ID: 10473804
[TBL] [Abstract][Full Text] [Related]
19. Oral tolerance to cancer can be abrogated by T regulatory cell inhibition.
Whelan MC; Casey G; Larkin JO; Guinn BA; O'Sullivan GC; Tangney M
PLoS One; 2014; 9(5):e97602. PubMed ID: 24832130
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
Hallett WHD; Ames E; Álvarez M; Barao I; Taylor PA; Blazar BR; Murphy WJ
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1088-1099. PubMed ID: 18804038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
